This report aims to provide a comprehensive presentation of the global market for Next-Generation Gynecological Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Gynecological Cancer Diagnostics. This report contains market size and forecasts of Next-Generation Gynecological Cancer Diagnostics in global, including the following market information:
Global Next-Generation Gynecological Cancer Diagnostics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Next-Generation Gynecological Cancer Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Ovarian Cancer Diagnosis Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Next-Generation Gynecological Cancer Diagnostics include Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Invitae Corporation, Konica Minolta, Inc., BGI Genomics, CENTOGENE N.V., Fulgent Genetics, Inc. and Illumina, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Next-Generation Gynecological Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Next-Generation Gynecological Cancer Diagnostics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Next-Generation Gynecological Cancer Diagnostics Market Segment Percentages, by Type, 2022 (%)
Ovarian Cancer Diagnosis
Cervical Cancer Diagnosis
Uterine Cancer Diagnosis
Global Next-Generation Gynecological Cancer Diagnostics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Next-Generation Gynecological Cancer Diagnostics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Next-Generation Gynecological Cancer Diagnostics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Next-Generation Gynecological Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Next-Generation Gynecological Cancer Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Next-Generation Gynecological Cancer Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Invitae Corporation
Konica Minolta, Inc.
BGI Genomics
CENTOGENE N.V.
Fulgent Genetics, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Laboratory Corporation of America Holdings
ARUP Laboratories
Myriad Genetics, Inc.
OPKO Health, Inc.
QIAGEN N.V.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Next-Generation Gynecological Cancer Diagnostics, market overview.
Chapter 2: Global Next-Generation Gynecological Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Next-Generation Gynecological Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Next-Generation Gynecological Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Next-Generation Gynecological Cancer Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Next-Generation Gynecological Cancer Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Next-Generation Gynecological Cancer Diagnostics Overall Market Size
2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Size: 2022 VS 2029
2.2 Global Next-Generation Gynecological Cancer Diagnostics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Next-Generation Gynecological Cancer Diagnostics Players in Global Market
3.2 Top Global Next-Generation Gynecological Cancer Diagnostics Companies Ranked by Revenue
3.3 Global Next-Generation Gynecological Cancer Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Next-Generation Gynecological Cancer Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Next-Generation Gynecological Cancer Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Next-Generation Gynecological Cancer Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Next-Generation Gynecological Cancer Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Next-Generation Gynecological Cancer Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Next-Generation Gynecological Cancer Diagnostics Market Size Markets, 2022 & 2029
4.1.2 Ovarian Cancer Diagnosis
4.1.3 Cervical Cancer Diagnosis
4.1.4 Uterine Cancer Diagnosis
4.2 By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2024-2029
4.2.3 By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Next-Generation Gynecological Cancer Diagnostics Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2024-2029
5.2.3 By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Next-Generation Gynecological Cancer Diagnostics Market Size, 2022 & 2029
6.2 By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2024-2029
6.2.3 By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2029
6.3.2 US Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.3.3 Canada Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.3.4 Mexico Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2029
6.4.2 Germany Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.4.3 France Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.4.4 U.K. Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.4.5 Italy Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.4.6 Russia Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.4.7 Nordic Countries Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.4.8 Benelux Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2029
6.5.2 China Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.5.3 Japan Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.5.4 South Korea Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.5.5 Southeast Asia Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.5.6 India Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2029
6.6.2 Brazil Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.6.3 Argentina Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2029
6.7.2 Turkey Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.7.3 Israel Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.7.4 Saudi Arabia Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
6.7.5 UAE Next-Generation Gynecological Cancer Diagnostics Market Size, 2018-2029
7 Next-Generation Gynecological Cancer Diagnostics Companies Profiles
7.1 Quest Diagnostics Incorporated
7.1.1 Quest Diagnostics Incorporated Company Summary
7.1.2 Quest Diagnostics Incorporated Business Overview
7.1.3 Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.1.4 Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Quest Diagnostics Incorporated Key News & Latest Developments
7.2 Thermo Fisher Scientific Inc.
7.2.1 Thermo Fisher Scientific Inc. Company Summary
7.2.2 Thermo Fisher Scientific Inc. Business Overview
7.2.3 Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.2.4 Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Thermo Fisher Scientific Inc. Key News & Latest Developments
7.3 Agilent Technologies, Inc.
7.3.1 Agilent Technologies, Inc. Company Summary
7.3.2 Agilent Technologies, Inc. Business Overview
7.3.3 Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.3.4 Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Agilent Technologies, Inc. Key News & Latest Developments
7.4 Invitae Corporation
7.4.1 Invitae Corporation Company Summary
7.4.2 Invitae Corporation Business Overview
7.4.3 Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.4.4 Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Invitae Corporation Key News & Latest Developments
7.5 Konica Minolta, Inc.
7.5.1 Konica Minolta, Inc. Company Summary
7.5.2 Konica Minolta, Inc. Business Overview
7.5.3 Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.5.4 Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.5.5 Konica Minolta, Inc. Key News & Latest Developments
7.6 BGI Genomics
7.6.1 BGI Genomics Company Summary
7.6.2 BGI Genomics Business Overview
7.6.3 BGI Genomics Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.6.4 BGI Genomics Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.6.5 BGI Genomics Key News & Latest Developments
7.7 CENTOGENE N.V.
7.7.1 CENTOGENE N.V. Company Summary
7.7.2 CENTOGENE N.V. Business Overview
7.7.3 CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.7.4 CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.7.5 CENTOGENE N.V. Key News & Latest Developments
7.8 Fulgent Genetics, Inc.
7.8.1 Fulgent Genetics, Inc. Company Summary
7.8.2 Fulgent Genetics, Inc. Business Overview
7.8.3 Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.8.4 Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Fulgent Genetics, Inc. Key News & Latest Developments
7.9 Illumina, Inc.
7.9.1 Illumina, Inc. Company Summary
7.9.2 Illumina, Inc. Business Overview
7.9.3 Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.9.4 Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.9.5 Illumina, Inc. Key News & Latest Developments
7.10 F. Hoffmann-La Roche Ltd
7.10.1 F. Hoffmann-La Roche Ltd Company Summary
7.10.2 F. Hoffmann-La Roche Ltd Business Overview
7.10.3 F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.10.4 F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.10.5 F. Hoffmann-La Roche Ltd Key News & Latest Developments
7.11 Laboratory Corporation of America Holdings
7.11.1 Laboratory Corporation of America Holdings Company Summary
7.11.2 Laboratory Corporation of America Holdings Business Overview
7.11.3 Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.11.4 Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.11.5 Laboratory Corporation of America Holdings Key News & Latest Developments
7.12 ARUP Laboratories
7.12.1 ARUP Laboratories Company Summary
7.12.2 ARUP Laboratories Business Overview
7.12.3 ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.12.4 ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.12.5 ARUP Laboratories Key News & Latest Developments
7.13 Myriad Genetics, Inc.
7.13.1 Myriad Genetics, Inc. Company Summary
7.13.2 Myriad Genetics, Inc. Business Overview
7.13.3 Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.13.4 Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.13.5 Myriad Genetics, Inc. Key News & Latest Developments
7.14 OPKO Health, Inc.
7.14.1 OPKO Health, Inc. Company Summary
7.14.2 OPKO Health, Inc. Business Overview
7.14.3 OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.14.4 OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.14.5 OPKO Health, Inc. Key News & Latest Developments
7.15 QIAGEN N.V.
7.15.1 QIAGEN N.V. Company Summary
7.15.2 QIAGEN N.V. Business Overview
7.15.3 QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Major Product Offerings
7.15.4 QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Revenue in Global Market (2018-2023)
7.15.5 QIAGEN N.V. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Next-Generation Gynecological Cancer Diagnostics Market Opportunities & Trends in Global Market
Table 2. Next-Generation Gynecological Cancer Diagnostics Market Drivers in Global Market
Table 3. Next-Generation Gynecological Cancer Diagnostics Market Restraints in Global Market
Table 4. Key Players of Next-Generation Gynecological Cancer Diagnostics in Global Market
Table 5. Top Next-Generation Gynecological Cancer Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Next-Generation Gynecological Cancer Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Next-Generation Gynecological Cancer Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Next-Generation Gynecological Cancer Diagnostics Product Type
Table 9. List of Global Tier 1 Next-Generation Gynecological Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Next-Generation Gynecological Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Next-Generation Gynecological Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Next-Generation Gynecological Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Next-Generation Gynecological Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Next-Generation Gynecological Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 30. Quest Diagnostics Incorporated Company Summary
Table 31. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 32. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. Quest Diagnostics Incorporated Key News & Latest Developments
Table 34. Thermo Fisher Scientific Inc. Company Summary
Table 35. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 36. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. Thermo Fisher Scientific Inc. Key News & Latest Developments
Table 38. Agilent Technologies, Inc. Company Summary
Table 39. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 40. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. Agilent Technologies, Inc. Key News & Latest Developments
Table 42. Invitae Corporation Company Summary
Table 43. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 44. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. Invitae Corporation Key News & Latest Developments
Table 46. Konica Minolta, Inc. Company Summary
Table 47. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 48. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. Konica Minolta, Inc. Key News & Latest Developments
Table 50. BGI Genomics Company Summary
Table 51. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 52. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. BGI Genomics Key News & Latest Developments
Table 54. CENTOGENE N.V. Company Summary
Table 55. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 56. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. CENTOGENE N.V. Key News & Latest Developments
Table 58. Fulgent Genetics, Inc. Company Summary
Table 59. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 60. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. Fulgent Genetics, Inc. Key News & Latest Developments
Table 62. Illumina, Inc. Company Summary
Table 63. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 64. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 65. Illumina, Inc. Key News & Latest Developments
Table 66. F. Hoffmann-La Roche Ltd Company Summary
Table 67. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 68. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 69. F. Hoffmann-La Roche Ltd Key News & Latest Developments
Table 70. Laboratory Corporation of America Holdings Company Summary
Table 71. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 72. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 73. Laboratory Corporation of America Holdings Key News & Latest Developments
Table 74. ARUP Laboratories Company Summary
Table 75. ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 76. ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 77. ARUP Laboratories Key News & Latest Developments
Table 78. Myriad Genetics, Inc. Company Summary
Table 79. Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 80. Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 81. Myriad Genetics, Inc. Key News & Latest Developments
Table 82. OPKO Health, Inc. Company Summary
Table 83. OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 84. OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 85. OPKO Health, Inc. Key News & Latest Developments
Table 86. QIAGEN N.V. Company Summary
Table 87. QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Product Offerings
Table 88. QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 89. QIAGEN N.V. Key News & Latest Developments
List of Figures
Figure 1. Next-Generation Gynecological Cancer Diagnostics Segment by Type in 2022
Figure 2. Next-Generation Gynecological Cancer Diagnostics Segment by Application in 2022
Figure 3. Global Next-Generation Gynecological Cancer Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Next-Generation Gynecological Cancer Diagnostics Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Next-Generation Gynecological Cancer Diagnostics Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue in 2022
Figure 8. By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 9. By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 10. By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 12. By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 14. By Region - Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 15. By Country - North America Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 16. US Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 20. Germany Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 21. France Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 28. China Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 32. India Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 34. Brazil Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 37. Turkey Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Next-Generation Gynecological Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 41. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
